Highest-materiality recent filing
Ultralife Q2 EPS $0.15 vs $0.05; record backlog $117.5M, gross margin up 500 bps
Sales $47.9M, down 1.3% YoY; gross margin 28.9% vs 23.9% (incl. $1.1M IEEPA refund).
Ultralife Q1 revenue $47.4M, GAAP EPS -$0.03; backlog record $115.1M
Revenue $47.4M, down 6.5% YoY; Battery & Energy sales -4.7%, Communications Systems -25.7%.
Ultralife Q4 revenue $48.5M, but operating loss of $10.6M on $12.2M impairment; GAAP EPS ($0.45)
Revenue $48.5M (+10.6% YoY); operating loss ($10.6M) vs profit $1.5M last year, driven by $12.2M intangible asset impairment.
Ultralife Q3 sales up 21.5% to $43.4M; GAAP loss per share of $0.07 on Calgary closure charge
Sales $43.4M (+21.5% YoY, including Electrochem); organic growth 2.5%. Backlog $90.1M vs $84.5M at Q2 2025.
Ultralife Q2 revenue up 13% to $48.6M on Electrochem; margin down, GAAP EPS $0.05 vs $0.18
Sales $48.6M (+13% YoY); organic Battery & Energy flat, Communications Systems down 57.2% to $2.7M.
Ultralife Q1 revenue $50.7M (+21% YoY); GAAP EPS $0.11 vs $0.18
Revenue $50.7M, up 21% YoY; Battery & Energy Products +32.4% to $46.3M (incl. Electrochem, organic +10.6%).
Ultralife Q4 GAAP EPS $0.01 vs $0.17 YoY; sales $43.9M; backlog $102.2M
Q4 sales $43.9M, down from $44.5M YoY; Battery & Energy +11.7%, Communications -55.1%.
Ultralife files amended 8-K with audited financials for Electrochem acquisition
Ultralife Corporation (ULBI) filed an 8-K/A on Jan 16, 2025, amending its Nov 6, 2024 report.
Ultralife Q3 EPS $0.02 vs $0.08; revenue $35.7M (-9.6%); backlog $78M
GAAP diluted EPS $0.02, down from $0.08; net income $0.3M vs $1.3M Q3 2023.
Ultralife completes $50M acquisition of Electrochem Solutions; secures $55M term loan
Acquired all shares of Electrochem from Integer Holdings (NYSE: ITGR) for $50M cash on Oct 31, 2024.
Ultralife acquires Electrochem Solutions for $50M; expects EPS accretive in 2025
Purchase price $50M cash; transaction expected to close by end of October 2024.
Ultralife Q2 sales $43.0M (+0.7%); Battery segment record; debt cut 52% to $12.1M
Sales $43.0M vs $42.7M; Battery & Energy Products segment record $36.7M, up 8.3% YoY.
Ultralife Q1 sales up 31.4% to $41.9M; GAAP EPS $0.18 vs -$0.02 YoY
Revenue $41.9M (+31.4% YoY); government/defense sales +83.4%, medical battery sales +54.7%.
Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03
Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.
Ultralife Q3 sales $39.5M (+18.8% YoY); operating income $2.1M vs loss
GAAP net income $1.3M ($0.08 diluted EPS) vs net loss of $0.2M a year ago.
Ultralife Q2 revenue $42.7M (+33% YoY); operating income $3.7M vs $0.8M; backlog record $110.9M
Revenue $42.7M, up 32.9% YoY; operating income $3.7M vs $0.8M YoY.
Ultralife Q1: revenue $31.9M (+5.1%), net loss $0.3M due to ransomware disruption
Revenue $31.9M, +5.1% YoY; operating income breakeven vs loss $0.3M last year.
Ultralife Q4 revenue up 52% to $36.1M; backlog record $111M; cyber incident caused 2-week disruption
Revenue $36.1M (+51.9% YoY); operating profit $0.2M vs loss $1.2M; net loss $0.2M ($0.01/sh) vs loss $1.1M ($0.07).
Ultralife names Michael E. Manna President & CEO; Popielec departs
Michael E. Manna appointed President & CEO and Board member effective November 22, 2022.
Ultralife awarded $5.5M vehicle comms systems order from U.S. Army prime contractor
Purchase order valued at about $5.5M from a global prime defense contractor for the U.S. Army.
Ultralife Q3 rev up 53% to $33.2M; net loss narrows to $0.2M but gross margin slides
Revenue $33.2M, up 53% YoY; net loss $0.2M ($0.01/share) vs loss $0.6M ($0.04) in Q3 2021.
Contract valued at approximately $7.5 million to supply A-320 amplifiers and A-320HVA radio vehicle mounts.
Ultralife awarded $4.6M order for Vehicle Amplifier-Adaptors from defense contractor
Purchase order valued at approximately $4.6 million for Ultralife's Vehicle Amplifier-Adaptor (VAA) platform.
Ultralife reports Q1 net loss of $0.2M on revenue $30.4M; backlog grows to $91.9M
Revenue $30.4M (+16.9% YoY); net loss $0.2M ($0.01 diluted) vs net income $0.7M ($0.04) in Q1 2021.
Ultralife files audited Excell financials: $18.5M sales, $1.5M net income for Feb-Dec 2021 stub
Sales $18.46M, gross profit $4.32M (23.4% margin), net income $1.49M for period Feb 1-Dec 12, 2021.
Ultralife Q4 revenue $23.8M, operating loss $1.2M; supply chain delays impacted results
GAAP net loss $1.1M ($0.07 loss per share) vs net income $2.1M ($0.13 EPS) in Q4 2020.
Ultralife acquires Excell Battery Group for $23.5M; expects EPS accretion within 12 months
Total purchase price of $23.5M for Excell Canada and Excell USA; funded by cash and new credit facilities.
Ultralife reports Q3 operating loss of $0.8M; revenue down 11% to $21.8M
Net loss $0.6M ($0.04/diluted share); adjusted EPS unfavorably impacted by $0.08 from supply chain delays.
Ultralife Q2 revenue $26.8M (-6.3% YoY); EPS $0.05 vs $0.10, supply chain delays
Revenue of $26.8M, down 6.3% YoY; operating income $1.1M vs $2.3M last year.
On February 21, 2023, the Board of Directors (the “Board”) of Ultralife Corporation (the “Company”) appointed Janie Goddard as an independent director of the Company effective as of February 21, 2023.
On November 22, 2022, the Board of Directors of Ultralife Corporation (the “Company”) appointed Michael E. Manna as the Company’s President & CEO and as a member of the Board of Directors, replacing Michael D. Popielec who is leaving the Company and resigning from his position as a member of the Board of Directors.
replacing Michael D. Popielec who is leaving the Company and resigning from his position as a member of the Board of Directors.
Max materiality 0.80 · Median 0.70 · Most common event earnings